Head and neck squamous cell carcinoma (HNSCC) · line 1 · Pembrolizumab monotherapy (HNSCC R/M, 1L; PD-L1 CPS ≥20)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	aggressive
Linked regimen	`REG-PEMBRO-MONO-HNSCC-1L`

ID	`IND-HNSCC-RM-1L-PEMBRO-MONO-CPS-HIGH`
Type	Indication
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	`DIS-HNSCC`
Sources	`SRC-NCCN-HNSCC-2025`

Notes

Alternative / aggressive-track 1L for the highest-PD-L1-expressing R/M HNSCC subset, where the chemo-sparing profile is durable and high-quality-of-life. Reuses DRUG-PEMBROLIZUMAB.

Used By

Algorithms

ALGO-HNSCC-RM-1L - ALGO-HNSCC-RM-1L

Indication

IND-LARYNGEAL-RM-1L-PEMBRO-MONO-CPS-HIGH - IND-LARYNGEAL-RM-1L-PEMBRO-MONO-CPS-HIGH